Addus HomeCare (ADUS) Q4 2025 earnings review
Scale Pays Off as Addus Surpasses $1.4 Billion in Annual Revenue
Addus closed out 2025 with strong momentum. Q4 revenue jumped 25.6% YoY to $373.1M, largely fueled by recent acquisitions (Gentiva, Del Cielo) and solid organic growth in Personal Care and Hospice. Bottom-line results were even more impressive: Adjusted EBITDA surged 33.3%, showcasing excellent G&A leverage despite slight gross margin compression. While the Home Health segment continues to struggle with declining volumes, the core Personal Care division is capitalizing on a stable macro environment with favorable state rate increases, pushing full-year Net Income up 30%.
🐂 Bull Case
Addus is proving it can digest large acquisitions efficiently. Q4 Adjusted EBITDA grew 33.3% on 25.6% revenue growth, driving Adjusted EBITDA margins to 13.5%—a significant expansion from 12.7% a year ago.
With a 9.9% rate increase in Texas (effective Sep 2025) and a 3.9% increase in Illinois (effective Jan 2026), the company's two largest markets have locked in substantial, high-margin revenue tailwinds for 2026.
🐻 Bear Case
The Home Health segment is moving in the wrong direction, with organic revenue growth reversing to -7.4% in Q4 and admission volumes dropping 7.5%.
Q4 Operating Cash Flow was just $18.8M, lagging far behind the $29.8M in Net Income. This poor conversion is driven by a swelling Accounts Receivable balance.
⚖️ Verdict: 🟢
Bullish. The core Personal Care and Hospice segments are accelerating, and management is successfully translating top-line scale from the Gentiva acquisition into bottom-line margin expansion. The Home Health weakness is a minor drag on an otherwise stellar quarter.
Key Themes
Favorable Macro Backdrop: State Rate Increases
State-level Medicaid reimbursement remains a highly stable macro tailwind. A 9.9% rate increase in Texas (effective September 1, 2025) and a 3.9% increase in Illinois (effective January 1, 2026) directly insulate the Personal Care segment's margins. Because Addus operates as a lower-cost alternative to institutional care, it continues to win state budget allocations despite broader federal spending uncertainties.
Hospice Segment Renaissance
The operational overhaul in the Hospice segment continues to yield Accelerating results. Q4 organic revenue growth hit a massive 16.0%, up from 7.8% a year ago. Revenue per patient day increased to $193.46 from $185.95, and patient days jumped nearly 12%. This high-margin segment is evolving into a reliable secondary growth engine.
Caregiver App Drives Utilization
Technology adoption is directly impacting the top line. The continued rollout of the company's proprietary caregiver mobile application is structurally improving the percentage of authorized hours actually served. By giving caregivers visibility into client capacity and shift scheduling, Addus is extracting more revenue from its existing patient base without relying solely on new client acquisition.
Operating Cash Flow Contradicts Profit Narrative
While management highlighted a 52.5% YoY surge in Net Income to $29.8M, the cash didn't follow. Operating Cash Flow came in at just $18.8M for the quarter. This Reversing cash conversion ratio was driven by a notable spike in Accounts Receivable, which ended the year at $151.7M (up 23% YoY). This suggests delayed collections or billing friction related to recent M&A integration.
Home Health Lags the Portfolio
Home Health is officially Decelerating into a deeper contraction. Organic revenue growth collapsed to -7.4% YoY in Q4, and total volume (admissions + recertifications) fell 7.5%. Management has previously cited CMS rate cut fears and integration struggles; this segment urgently requires a strategic fix before it begins eroding consolidated margins.
Gross Margin Compression Masked by Scale
Gross margin compressed to 33.1% in Q4 from 34.2% a year ago, primarily due to the mix shift incorporating the lower-margin Gentiva Personal Care assets. However, Addus successfully offset this through massive G&A leverage (dropping to 20.7% of revenue from 24.0% YoY), driving Adjusted EBITDA margins higher overall.
Disciplined M&A Engine
The October 1, 2025 acquisition of Del Cielo Home Care seamlessly bolted onto the Texas operations, adding to the massive Gentiva acquisition completed in late 2024. These deals are the primary reason total billable hours surged 34% YoY in Q4, establishing Addus as the undisputed market leader in Texas Personal Care.
Other KPIs
Accelerating dramatically from 8.21 million in 24Q4. This 34% volume jump reflects both the Gentiva/Del Cielo integrations and steady mid-single-digit organic hiring growth. Revenue per billable hour dipped slightly to $25.70 from $26.40 YoY, reflecting the lower-reimbursement mix of the Texas assets, but will benefit from the recent 9.9% Texas rate hike moving forward.
Stable. Total bank debt was aggressively paid down from over $200 million earlier in the year. The company holds $517.7 million in available revolver capacity, maintaining a highly conservative leverage profile (<1x Net Debt/EBITDA) that easily supports further M&A in 2026.
Guidance
Effective January 1, 2026. This acts as a structural margin floor and top-line accelerant for the company's largest historic market, guaranteeing pricing power in an environment where inflation is cooling.
Key Questions
Accounts Receivable Build
With Accounts Receivable growing 23% YoY and dragging down Q4 operating cash flow, what specific payer or state is driving this delay, and when do you expect DSOs to normalize?
Home Health Strategy
Given the 7.5% volume decline and -7.4% organic growth in Home Health, is this segment still considered a core pillar of the 'continuum of care' strategy, or is it a candidate for divestiture?
M&A Pipeline Focus
With leverage comfortably below 1x, are you prioritizing further Personal Care density in Texas, or are you looking to buy depressed Home Health/Hospice assets that are suffering from CMS rate uncertainties?